Adverse Effects of Lipid-lowering Agents and Corresponding Management

doi:10.3969/j.issn.1007-9572.2016.36.002

Abstract

Abstract: For nearly three decades, lipid-lowering agents, especially statins, have been widely used for regulating blood lipids and preventing atherosclerosis for their safety and efficacy in lowering low-density lipoprotein cholesterol (LDL-C) and elevating high-density lipoprotein cholesterol (HDL-C), thwarting lipid infiltration and deposition in the vascular wall and stabilizing plaques. However, the adverse effects of this kind of drugs have been revealed by clinical trials and clinical applications, subsequently their clinical application has been limited. This paper elaborates on the adverse effects of lipid-lowering agents and the corresponding management measures, so as to provide guiding suggestions for clinicians to use such drugs scientifically and rationally.

Key words: Lipid regulating agents, Adverse drug reaction, Guidelines

摘要： 调脂药物应用于调整血脂以防治动脉粥样硬化已有近 30 年的历史，尤其是他汀类调脂药物，由于其能安全、有效地降低低密度脂蛋白胆固醇（LDL-C）、升高高密度脂蛋白胆固醇（HDL-C）、阻止脂质浸润沉积血管壁以及稳定斑块等，目前在临床应用广泛。但临床研究及临床实践均提示其存在不良反应，使其临床应用受到限制。本文通过详述调脂药物的不良反应及其处理措施，为临床医生科学合理应用该类药物提供指导建议。

关键词: 调脂药, 药物不良反应, 指南

NIU Ya-qian-qian, GUO Dan-jie. Adverse Effects of Lipid-lowering Agents and Corresponding Management[J]. Chinese General Practice, 2016, 19(36): 4416-4419.

牛亚芊芊, 郭丹杰. 调脂药物的不良反应及其处理措施[J]. 中国全科医学, 2016, 19(36): 4416-4419.

References

［1］CATAPANO A L,GRAHAM I,DE BACKER G,et al.2016 ESC/EAS Guidelines for the Management of Dyslipidaemias:The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology （ESC） and European Atherosclerosis Society （EAS） Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation （EACPR）［J］.Atherosclerosis,2016.［Epub ahead of print］.DOI:10.1093/eurheartj/ehw272. ［2］他汀类药物安全性评价工作组.他汀类药物安全性评价专家共识［J］.中华心血管病杂志，2014,42（11）：890-894. Working Group on Safety Evaluation of Statins.Expert consensus on safety evaluation of statins［J］.Chin J Cardiol,2014,42（11）：890-894.DOI:10.3760/cma.j.issn.0253-3758.2014.11.002. ［3］PARKER B A,CAPIZZIJ A,GRIMALDI A S，et al.Effect of statins on skeletal muscle function［J］.Circulation，2013,127（1）:96-103. ［4］ROSENSON R S,BAKER S K,JACOBSON T A,et al.An assessment by the Statins Muscle Safety Task Force:2014 update［J］.J Clin Lipidol,2014,8（3 Suppl）:S72-81. ［5］2014年中国胆固醇教育计划血脂异常防治建议专家组，中华心血管病杂志编辑委员会，血脂与动脉粥样硬化循证工作组，等.2014年中国胆固醇教育计划血脂异常防治专家建议［J］.中华心血管病杂志,2014,42（8）：633-636. Expert Group on Prevention and Treatment of Dyslipidemia in China’s Cholesterol Education Program in 2014，Editorial board of Chinese Journal of Cardiology，The Working Group of Evidence Based on Blood Lipid and Atherosclerosis，et al.Expert advice on prevention and treatment of dyslipidemia in China’s cholesterol education program in 2014［J］.Chin J Cardiol,2014,42（8）:633-636. 10.3760/cma.j.issn.0253-3758.2014.08.003. ［6］STROES E S,THOMPSON P D,CORSINI A，et al.Statin-associated muscle symptoms：impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment,Aetiology and Management［J］.Eur Heart J,2015,36（17）:1012-1022.DOI:10.1093/eurheartj/ehv043. ［7］THOMPSON P D,PANZA G,ZALESKI A,et al.Statin-associated side effects［J］.J Am Coll Cardiol,2016,67（20）:2395-2410. ［8］STONE N J,ROBINSON J G,LICHTENSTEIN A H,et al.2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines［J］.J Am CollCardiol,2014,63（25 Pt B）:2889-2934. ［9］RAHAL A J,ELMALLAH A I,POUSHUJU R J,et al.Do statins really cause diabetes? A meta-analysis of major randomized controlled clinical trials［J］.Saudi Med J,2016,37（10）:1051-1060. ［10］ MAKI K C,RIDKER P M,BROWN W V，et al.An assessment by thestatin diabetes safety task force：2014 update［J］.J Clin Lipidol,2014,8（3）:72-81. ［11］BITZUR R.Remembering statins:do statins have adverse cognitive effects?［J］.Diabetes Care,2016,39 Suppl 2:S253-259. ［12］WONG M G,PERKOVIC V.Knowing what we do not know:statin therapy in advanced chronic kidney disease［J］.Lancet Diabetes Endocrinol,2016,4（10）:801-803.

[1]	ZHANG Ying, YANG Ziyu, LIU Lidi, LIAO Xiaoyang, JIA Yu, SHEN Can, YANG Rong. Interpretation of the Consensus Statement Physical by American College of Sports Medicine on Adults Activity and Excess Body Weight and Adiposity [J]. Chinese General Practice, 2026, 29(03): 293-298.
[2]	ZHANG Ying, LIAO Xiaoyang, YANG Hanfei, YU Yongjun, LIU Lidi, JIA Yu, SHEN Can, LI Xiao, HUANG Chuanying, YANG Rong. Interpretation of the 2024 International Society of Hypertension Position Paper on Innovations in Blood Pressure Measurement and Reporting Technology and Its Implications for China [J]. Chinese General Practice, 2025, 28(36): 4541-4549.
[3]	HE Yuling, LIN Meiqun, LUO Huiyu, HUANG Wenting, JIANG Liqin, ZHU Hongyu. Systematic Review of Guidelines for the Management of Patients with Cancer Pain [J]. Chinese General Practice, 2025, 28(33): 4199-4205.
[4]	ZHI Congcong, CHENG Yicheng, HUANG Zichen, WANG Xiaolong, LI Xue, ZHENG Lihua. Collection and Determination of Clinical Questions and Outcome Indicators Based on the Guidelines for Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Hemorrhoids (2025 Edition) [J]. Chinese General Practice, 2025, 28(32): 4089-4094.
[5]	LUO Qi, CHEN Xiaolei, ZHAO Linlin, DU Juan, SHAO Shuang. Systematic Evaluation of Social Capital Assessment Tools for Elderly Based on COSMIN Guidelines [J]. Chinese General Practice, 2025, 28(31): 3974-3980.
[6]	CAO Qinhan, ZHUO Xiao, XIA Yuhan, CHE Yangxi, CHEN Min. Interpretation of Updated NCCN Clinical Guidelines for Rectal Cancer (2024.V1/V2) [J]. Chinese General Practice, 2025, 28(17): 2070-2074.
[7]	MA Guifen, ZHANG Qian, SUN Jing. Interpretation of the Key Updates in the Latest Version of 2024 NCCN Clinical Practice Guidelines for Gastric Cancer [J]. Chinese General Practice, 2025, 28(14): 1681-1688.
[8]	Chinese Academy Society of Sleep Medicine, Chinese Medical Doctor Association, Sleep Medicine Group, China Neurologist Association. Chinese Guideline for Diagnosis and Treatment of Co-morbid Insomnia and Obstructive Sleep Apnea (2024) [J]. Chinese General Practice, 2025, 28(11): 1289-1303.
[9]	Phillips William R., Sturgiss Elizabeth, Glasziou Paul, olde Hartman Tim C., Orkin Aaron M., Prathivadi Pallavi, Reeve Joanne, Russell Grant M., van Weel Chris. Improving the Reporting of Primary Care Research: Consensus Reporting Items for Studies in Primary Care—the CRISP Statement [J]. Chinese General Practice, 2025, 28(04): 385-392.
[10]	GAO Yicheng, YU Zijin, CAO Rui, LIU Zhihan, FANG Rui, LI Yuanyuan, DENG Yingjie, XIANG Wenyuan, FEI Yutong. Thinking and Methodological Suggestions of Empirical Research in the Development of Clinical Practice Guidelines [J]. Chinese General Practice, 2025, 28(04): 402-406.
[11]	MA Huping, REN Rong, HOU Mei, YUAN Aiyun. Clinical Observation of the New Antiepileptic Drug Perampanel in the Treatment of Refractory Epilepsy in Children Aged 0-18 Years [J]. Chinese General Practice, 2025, 28(02): 250-256.
[12]	PENG Tao, ZOU Chuan, ZENG Xin, ZHANG Yan, SHEN Jing. A Controlled Study of Salon-training Models Based on the Calgary-Cambridge Guidelines for Improving Patient-physician Communication Skills in General Practice [J]. Chinese General Practice, 2025, 28(01): 71-76.
[13]	QIN Xiaokuan, SUN Kai, FENG Tianxiao, XIAO Xiangyu, WANG Guochen, SU Xiangfei, WEI Xu, ZHU Liguo. Methodological Quality Evaluation and Comprehensive Analysis of Clinical Practice Guidelines and Expert Consensus for Lumbar Disc Herniation [J]. Chinese General Practice, 2024, 27(31): 3857-3864.
[14]	FENG Tianxiao, SUN Kai, QIN Xiaokuan, WANG Xu, BU Hanmei, ZHU Liguo, WEI Xu. Development Status, Challenges, and Strategies of Clinical Practice Guidelines in Traditional Chinese Medicine Orthopedics [J]. Chinese General Practice, 2024, 27(31): 3850-3856.
[15]	WU Taiqin, GAN Xiuni, GAO Yan, ZHANG Huan, YANG Li. Interpretation of the 2023 ESPEN Guideline on Nutritional Support for Polymorbid Medical Inpatients [J]. Chinese General Practice, 2024, 27(21): 2557-2564.